Arcus Biosciences eyes $100M IPO

Arcus Biosciences is working on small-molecule and immuno-oncology approaches with the goal of creating combo treatments for cancer. (Natalie Murphy)

Mere months after bagging $107 million in its series C round, Arcus Biosciences is teeing up for a $100 million IPO.

The series C funding was slated to advance its lead programs—AB928, a first-in-class dual adenosine receptor antagonist, and AB122, a PD-1 antibody—and to carry “at least two” additional drugs into the clinic.

As for its IPO cash, it will enable the immuno-oncology player to fund clinical studies for AB928 and AB122 into 2020, but not support the candidates through regulatory approval, according to an S-1 filed Friday.

Webinar

Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

AB928 and AB122 are both in phase 1 trials, which are expected to read out this year. The former will enter a phase 1/2 study in the second quarter, and a treatment combining the two is also on deck for phase 1/2.

The Hayward, Calif.-based biotech counts Google Ventures, Aisling Capital and Celgene among its backers and emerged from stealth in August 2016 with $120 million already in the bank. Its strategy is to develop small molecules and immuno-oncology therapies with the eventual goal of creating its own combo treatments.

RELATED: FierceBiotech's 2016 Fierce 15 - Arcus Biosciences

“Everyone knows that combinations are important, but it’s become apparent that in immuno-oncology it may be advantageous to own or control parts of the combination,” Arcus CEO Terry Rosen told FierceBiotech when Arcus was named a Fierce 15 winner in 2016.

Shortly before its series C raise, Arcus bolstered its cancer immunotherapy pipeline with an exclusive licensing deal potentially worth $816 million. The company handed over $18.5 million up front for the European, North American and Japanese rights to a PD-1 antibody developed at China’s Gloria Pharma and WuXi Biologics. Arcus plans to test the drug, GLS-010, in 11 cancer combo treatments.

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.